Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Healthtrust
Accenture
Merck
McKesson
Farmers Insurance
Argus Health
Novartis
QuintilesIMS
US Army

Generated: October 19, 2017

DrugPatentWatch Database Preview

Vertex Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for VERTEX PHARMS, and what generic alternatives to VERTEX PHARMS drugs are available?

VERTEX PHARMS has four approved drugs.

There are twenty US patents protecting VERTEX PHARMS drugs.

There are three hundred and twenty-seven patent family members on VERTEX PHARMS drugs in forty-one countries and thirty-two supplementary protection certificates in thirteen countries.

Summary for Applicant: Vertex Pharms

International Patents:327
US Patents:20
Tradenames:3
Ingredients:3
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-002Mar 17, 2015RXYesYes► Subscribe► Subscribe ► Subscribe
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-001Mar 17, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-001Mar 17, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Vertex Pharms
INCIVEK
telaprevir
TABLET;ORAL201917-001May 23, 2011DISCNNoNo► Subscribe► SubscribeYY ► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Vertex Pharms
KALYDECO
ivacaftor
TABLET;ORAL203188-001Jan 31, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Vertex Pharms Inc
KALYDECO
ivacaftor
GRANULE;ORAL207925-002Mar 17, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-001Jul 2, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Vertex Pharms Inc
ORKAMBI
ivacaftor; lumacaftor
TABLET;ORAL206038-002Sep 28, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expirations for VERTEX PHARMS

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Vertex Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,741,925Modulators of ATP-binding cassette transporters► Subscribe
8,461,156Modulators of ATP-binding cassette transporters► Subscribe
8,318,733Modulators of ATP-binding cassette transporters► Subscribe
7,956,052Modulators of ATP-binding cassette transporters► Subscribe
2,014,187,770► Subscribe
9,090,619Modulators of ATP-binding cassette transporters► Subscribe
8,012,999Modulators of CFTR► Subscribe
9,434,717Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl) benzoic acid► Subscribe
8,252,923Peptidomimetic protease inhibitors► Subscribe
9,139,530Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Vertex Pharms Drugs

Country Document Number Estimated Expiration
Spain2489115► Subscribe
Australia2009296271► Subscribe
China101006076► Subscribe
Japan4689938► Subscribe
Denmark1773816► Subscribe
China101910156► Subscribe
South Korea100945975► Subscribe
Australia2006311650► Subscribe
Israel215890► Subscribe
China102652128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Vertex Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
073Luxembourg► SubscribePRODUCT NAME: ACIDE BENZOIQUE 3-{6-{-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPANECARBONYL AMINO}-3-METHYLPYRIDIN-2-YL}, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, OU UN PRO-MEDICAMENT DE TYPE ESTER DE CELUI-CI; FIRST REGISTRATION DATE: 20151124
2016000035Germany► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOESAEURE, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, ODER EIN ESTER-PRODRUG DAVON.; REGISTRATION NO/DATE: EU/1/15/1059 20151119
761Luxembourg► SubscribePRODUCT NAME: N-(5-HYDROXY-2,4-DIERT-BUTYL-PHENYL)-4OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; FIRST REGISTRATION: 20120725
C0020France► SubscribePRODUCT NAME: LUMACAFTOR, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU SES PROMEDICAMENTS ESTERS; REGISTRATION NO/DATE: EU/1/15/1059 20151124
00518Netherlands► SubscribePRODUCT NAME: TELAPREVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN/OF SOLVAAT DAARVAN, OF SOLVATEN VAN DERGELIJKE ZOUTEN; REGISTRATION NO/DATE: EU/1/11/720/001 2011190919
C0018France► SubscribePRODUCT NAME: TELAPREVIR ET LES SELS ET/OU LES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DU TELAPREVIR OU LES SOLVATES DE TELS SELS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
2015000050Germany► SubscribePRODUCT NAME: N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-CHINOLIN-3-CARBONSAEUREAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723
0812Netherlands► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124
2016 00019Denmark► SubscribePRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPANCATBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOSYRE, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ELLER ET ESTERPRODRUG DERAF; REG. NO/DATE: EU/1/15/1059 20151124
2012003Lithuania► SubscribePRODUCT NAME: TELAPREVIRUM; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chubb
McKesson
Moodys
Colorcon
Citi
Cerilliant
Daiichi Sankyo
Fuji
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot